MARKET

CERO

CERO

CERo Therapeutics
NASDAQ
1.370
-0.040
-2.84%
After Hours: 1.380 +0.01 +0.73% 19:50 04/26 EDT
OPEN
1.420
PREV CLOSE
1.410
HIGH
1.470
LOW
1.370
VOLUME
94.32K
TURNOVER
0
52 WEEK HIGH
12.80
52 WEEK LOW
1.330
MARKET CAP
20.17M
P/E (TTM)
-3.5264
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CERO last week (0415-0419)?
Weekly Report · 5d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out on Thursday morning. Tian Ruixiang stock is rocketing 151% after announcing plans for an extraordinary general shareholders meeting. MicroCloud Hologram shares are soaring over 52% with heavy pre-market trading. Moving stocks this morning are earnings reports, shareholder meetings, public offerings and more.
Investorplace · 04/18 11:27
Weekly Report: what happened at CERO last week (0408-0412)?
Weekly Report · 04/15 09:35
CERo Therapeutics files to sell 26.62M shares of common stock
Healthcare CERo Therapeutics files to sell 26.62M shares of common stock Apr. 10, 2024 4:23 p.m. The company filed a prospectus related to the offer and sale of 26.60 million shares of stock. This is not an offer to sell.
Seeking Alpha · 04/10 20:23
CERO THERAPEUTICS FILES PROSPECTUS RELATES TO POTENTIAL OFFER, SALE FROM TIME TO TIME BY KEYSTONE CAPITAL PARTNERS OF UP TO 25.6 MLN COMMON SHARES
Reuters · 04/10 20:09
Weekly Report: what happened at CERO last week (0401-0405)?
Weekly Report · 04/08 09:37
NVCR, SBNY and VITL are among after hour movers
On the Move NVCR, SBNY and VITL are among after hour movers. Zapata Computing and Vital Farms are among the gainers. Signature Bank loses 11% of its value in the last 12 hours. The market is down 1% in the past day.
Seeking Alpha · 04/01 21:08
Weekly Report: what happened at CERO last week (0325-0329)?
Weekly Report · 04/01 09:37
More
About CERO
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.

Webull offers CERo Therapeutics Holdings Inc stock information, including NASDAQ: CERO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CERO stock methods without spending real money on the virtual paper trading platform.